Treated white coat effect not tied to cardiovascular events or all-cause, cardiovascular mortality
In a study, 87% of hyperkalemic patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy were able to continue or increase their RAASi doses while concurrently taking sodium zirconium cyclosilicate.
Fibroblast growth factor 23 levels above the median are independently associated with shorter 6-minute walk distance and lower peak oxygen consumption on exercise testing, study finds.
Highest risk for cardiovascular disease mortality seen for those with work stress and impaired sleep
Users of atenolol had 59% and 55% decreased odds of intermediate- and high-risk prostate cancer being found on biopsy compared with nonusers.
Overall death from any cause reduced, regardless of cardiovascular risk
But no association observed between sleep duration or quality and change in BP drug use
Targeting a systolic blood pressure below 130 mm Hg was associated with a 21% decreased risk of all-cause mortality among patients with stage 3 to 4 chronic kidney disease, a meta-analysis found.
For those on antihypertensive treatment, cognitive decline greater with SBP <130 versus >150 mm Hg
Blood pressure values less than 140/90 mm Hg tied to increased mortality risk for octogenarians